Published in Biotech Law Weekly, July 2nd, 2004
In addition, 62% of this "no-treatment" group received antidepressants, which are contraindicated with bipolar disorder treatment guidelines.
Further analysis presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 9th annual meeting in Arlington, Virginia, showed that, compared with use of mood stabilizer monotherapy, use of newer...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.